SB2044 amends the Oklahoma Chiropractic Practice Act to revise the grounds and procedures for disciplining chiropractic physicians. The bill keeps the Board of Chiropractic Examiners’ authority to impose penalties such as license denial, suspension, revocation, fines, censure, probation, and cost recovery, but it adds a new exception and clarifying language around one of the disciplinary grounds. In particular, the bill specifies that a chiropractic physician may possess, prescribe, or administer vitamins, minerals, nutritional supplements, and similar solutions, while making clear that nothing in the section authorizes the administration of drugs, medicines, serums, or vaccines.
The bill also updates and restates several existing grounds for discipline, including criminal convictions, substance abuse, misleading advertising, unauthorized practice, prohibited instruments, fraudulent licensure, unfair claims settlement violations, aiding improper insurance claim denials, and violations of the Chiropractic Practice Act or Board rules. It preserves the right to judicial review of Board orders and authorizes the Board to issue confidential letters of concern when conduct does not yet justify formal proceedings. It also requires expungement of complaints and related records if the Board does not issue a penalty order within three years of receiving a complaint.
The bill’s impact on state law is primarily regulatory: it narrows and clarifies the scope of chiropractic disciplinary authority while preserving the Board’s enforcement tools. It affects chiropractic physicians, the Board of Chiropractic Examiners, and indirectly patients and insurers by reinforcing professional standards and clarifying what treatments and substances are within the lawful scope of chiropractic practice. The effective date is November 1, 2026.
Overall sentiment appears broadly supportive. The bill passed the Senate unanimously on third reading and advanced through committee with favorable votes, suggesting little opposition to the measure as amended. The committee history indicates the bill was refined through a committee substitute, which may reflect technical or policy adjustments rather than major controversy.
The main point of contention appears to be the scope of what chiropractic physicians may possess or administer, especially the distinction between permitted vitamins/minerals/nutritional supplements and prohibited drugs, medicines, serums, and vaccines. Another possible area of concern is the bill’s inclusion of insurance-related misconduct and the new three-year expungement rule, both of which affect how complaints and enforcement actions are handled by the Board.
SB2044 amends 59 O.S. 2021, Section 161.12, within the Oklahoma Chiropractic Practice Act. It preserves the Board of Chiropractic Examiners’ disciplinary powers while clarifying that chiropractors may handle vitamins, minerals, and nutritional supplements without that authority being read to permit drugs, medicines, serums, or vaccines. It also adds a confidential letter-of-concern process and requires expungement of complaints and related records if no penalty order is issued within three years, affecting Board enforcement procedures and recordkeeping.
The bill appears to have received generally favorable treatment in both chambers and committee. It passed the Senate 44-0 on third reading and received a strong committee vote in the Senate, then advanced in the House Public Health Committee as amended. The available voting history suggests broad agreement with the bill’s clarifying and procedural changes, with no recorded floor opposition.
The most notable substantive issue is the boundary of chiropractic practice, especially the bill’s explicit allowance for vitamins, minerals, and nutritional supplements versus its continued prohibition on drugs, medicines, serums, and vaccines. There is also potential concern about the bill’s disciplinary provisions involving insurance claims and the Board’s authority to issue confidential letters of concern and expunge complaints after three years, which may be viewed as either consumer-protective or restrictive depending on perspective.